FDMT4D Molecular Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of 4D Molecular Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDMTThis | — | — | — | — | 230194.6%#1 | 12.9%#3 | -187.2%#3 | -34.4%#4 | -44.7%#1 | — | 100.4%#2 | — |
| MGTX | $1.2B#2 | 14.7x#1 | — | 15.1x#2 | 144.6%#2 | 22.7%#2 | -130.2%#2 | — | — | — | 74.1%#4 | — |
| GLUE | $1.1B#3 | — | 2.3x#2 | 9.0x#1 | 63.5%#3 | 46.9%#1 | -43.8%#1 | -7.9%#3 | — | — | 87.8%#3 | — |
| REPL | $1.2B#1 | — | 11.6x#6 | — | — | -26.9%#6 | — | -297.1%#7 | -7270.9%#2 | — | 130.1%#1 | — |
| ODTX | $1.1B#4 | — | 2.5x#4 | — | — | — | — | 0.0%#1 | — | — | — | — |
| SANA | $949M#5 | — | 6.1x#5 | — | — | 8.5%#4 | — | -158.0%#6 | — | — | -1.9%#6 | — |
| SLDB | $896M#6 | — | 2.4x#3 | 110.7x#3 | -40.6%#5 | -39.8%#7 | -2214.1%#4 | -46.6%#5 | — | — | 52.1%#5 | — |
| PRME | $571M#7 | — | 14.4x#7 | 123.3x#4 | 55.3%#4 | -2.7%#5 | -4498.1%#5 | -505.3%#8 | — | — | -21.4%#7 | — |
| EIKN | $513M#8 | — | 1.1x#1 | — | — | — | — | 0.0%#1 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice